Literature DB >> 2338028

Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet.

N S Wang1, X B Guo, Q D Liu, L C Fu, G Q Li, K Arnold.   

Abstract

The oral single-dose pharmacokinetics and bioavailability of mefloquine (M) in combination with pyrimethamine (P) and sulfadoxine (S) from a single non-lacquered tablet (NL; M 250 mg, P 25 mg, S 500 mg) and two lacquered tablets (L; M 125 mg, P 12.5 mg, S 250 mg) were investigated in 6 healthy Chinese volunteers. The plasma concentrations of P and S were measured by high-performance liquid chromatography with UV detector over 11 days and the plasma concentrations of M were measured by gas chromatography with electron capture for 63 days. The pharmacokinetic evaluation of each of the three components was based on the assumption of an open linear one-compartment model. The model-independent pharmacokinetic parameters such as elimination half-life and total clearance of P and S in the present study were not appreciably different from those reported previously. The pharmacokinetic parameters of elimination half-life, total clearance and apparent volume of distribution of M were 11 days, 45.8 ml/h.kg, and 14.8 l/kg, respectively. Compared to previously published data on M in Thai patients, Caucasian, Brazilian and African subjects, it was found that the elimination half-life in Chinese subjects was similar to that in Thai patients, but different from Caucasian, Brazilian and African subjects. There were significant differences in total clearance and volume of distribution among Chinese subjects and Thai patients. The differences in pharmacokinetic behaviour of M between subject groups needs to be examined further. The relative bioavailability of P, S, and M in the lacquered and non-lacquered tablet formulations in the 6 subjects studied were not significantly different with values (mean +/- SD) of 0.98 +/- 0.06, 1.28 +/- 0.20 and 1.02 +/- 0.17, respectively.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338028     DOI: 10.1159/000238764

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  4 in total

1.  Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women.

Authors:  Harin A Karunajeewa; Sam Salman; Ivo Mueller; Francisca Baiwog; Servina Gomorrai; Irwin Law; Madhu Page-Sharp; Stephen Rogerson; Peter Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

2.  Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group.

Authors:  R McLeod; D Mack; R Foss; K Boyer; S Withers; S Levin; J Hubbell
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

3.  Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine.

Authors:  J R Veenendaal; A D Parkinson; N Kere; K H Rieckmann; M D Edstein
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Modulation of brain cation-Cl- cotransport via the SPAK kinase inhibitor ZT-1a.

Authors:  Jinwei Zhang; Mohammad Iqbal H Bhuiyan; Ting Zhang; Jason K Karimy; Zhijuan Wu; Victoria M Fiesler; Jingfang Zhang; Huachen Huang; Md Nabiul Hasan; Anna E Skrzypiec; Mariusz Mucha; Daniel Duran; Wei Huang; Robert Pawlak; Lesley M Foley; T Kevin Hitchens; Margaret B Minnigh; Samuel M Poloyac; Seth L Alper; Bradley J Molyneaux; Andrew J Trevelyan; Kristopher T Kahle; Dandan Sun; Xianming Deng
Journal:  Nat Commun       Date:  2020-01-07       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.